Demystifying TELA Bio: Insights From 6 Analyst Reviews
Portfolio Pulse from Benzinga Insights
TELA Bio (NASDAQ:TELA) has been the subject of recent analyst reviews, with 6 analysts providing ratings ranging from bullish to bearish. The average 12-month price target has decreased by 16.48% to $11.0. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. TELA Bio, a medical technology company, has shown revenue growth but faces challenges with profitability, debt management, and returns on equity and assets.
October 04, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
TELA Bio has received mixed analyst ratings, with a decrease in the average price target to $11.0. Analysts have adjusted their ratings due to market dynamics and company performance. Despite revenue growth, TELA Bio faces challenges in profitability, debt management, and returns on equity and assets.
The decrease in the average price target and the lowering of ratings by several analysts suggest a negative short-term outlook for TELA Bio. The company's financial challenges, such as low profitability and high debt, further support a likely decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100